Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>On March 31, 2026, Soligenix, Inc. (SNGX) announced financial results for the year ending December 31, 2025 and provided a business update.</li><li>The company has a number of important clinical readouts and milestones ahead in 2026.</li><li>We anticipate an interim analysis for the ongoing Phase 3 FLASH2 trial of HyBryte in the treatment of cutaneous T-cell lymphoma (CTCL) in the second quarter of 2026 and topline results from the trial are expected in the second half of 2026.</li></ul>

On March 31, 2026, Soligenix, Inc. (SNGX) announced financial results for the year ending December 31, 2025 and provided a business update.The company has a number of important clinical readouts and milestones ahead in 2026.We anticipate an interim analysis for the ongoing Phase 3 FLASH2 trial of HyBryte in the treatment of cutaneous T-cell lymphoma (CTCL) in the second quarter of 2026 and topline results from the trial are expected in the second half of 2026.

SNGX: 2026년 2분기 CTCL 3상 임상시험 중간 분석 결과 발표 예정